Floatz logo

CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE

MCRPC (metastatic Castration-resistant Prostate Cancer)

Ding-Wei YeSmall moleculePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
89/ 100

Competitive context

229 Active assets in the MCRPC (metastatic Castration-resistant Prostate Cancer) cohort.

Asset / SponsorPhaseRating
Darolutamide
Bayer
Phase 4BBB
Enzalutamide
Prostate Cancer Clinical Trials Consortium
Phase 4BBB
Darolutamide
Bayer
Phase 3BB
RADIUM RA-223
Bayer
Phase 4BB
RADIUM RA-223
University of California, San Francisco
Phase 4BB

View all 50 →

Same molecule, other indications

CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE is also rated in:

infantile spasmsDormant
BBB
Indicative ·
79 / 100
View asset →
non-Hodgkin lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →